Translational research such as that proposed in the Melanoma and Skin Program (MSCP) SPORE has a spectrum of needs that benefit from software solutions, including clinical information annotation, data warehousing and disease modeling/analysis tools. The informatics Core (Core D) will serve the Projects and Cores of the MSCP SPORE in the following ways: Project 1. The Informatics Core will be responsible for the data extraction and clinical annotations by the Research Information Service (RIS) to support the El609 patient cohort and ensure the integration of these data into the Research Data Warehouse (RDW) for use by Biostatistics Core (Core C). Project 2. The Informatics Core will assist in studying the management of the toxicities associated with the treatment in the Project 2 cohorts using our clinical phenotyping tool. This project also requires use the Core D's Clinical Trials Management Application (CTMA) and our clinical annotation expertise provided by the RIS. Of note, CTMA will serve all of the Projects'Clinical Research Management System (CRMS) needs. Project 3. Core D will provide access to the clinical annotation data for Project 3 and make these data available to the SPORE team as well as the Biostatistics Core. The study will collect data electronically from our Electronic Medical Record (EMR) systems and analyze it with our cohort discovery tool (GIANT). The research data generated from this project will also be incorporated into our RDW. Project 4. Core D will develop algorithms (via GIANT) to identify patients with in transit melanoma that may be eligible for inclusion in this project and coordinate the collection of clinical annotations from RIS. Core A (Administrative). The Informatics Core will ensure requisite trial data are recorded, stored, backed up, and available for review and annual reporting by the Project PIs to the Internal and External Advisory Boards and the National Cancer Institute. In addition, the Informatics Core will be responsible for all network storage and data sharing within the MSCP SPORE and for Intra-SPORE collaborations and will support the Developmental Research and Career Development Projects managed in Core A.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA121973-06
Application #
8554645
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2006-07-01
Project End
2018-06-30
Budget Start
2013-09-17
Budget End
2014-06-30
Support Year
6
Fiscal Year
2013
Total Cost
$126,764
Indirect Cost
$43,425
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Retseck, Janet; VanderWeele, Robert; Lin, Hui-Min et al. (2016) Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer 4:38
Scharping, Nicole E; Menk, Ashley V; Moreci, Rebecca S et al. (2016) The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity 45:374-88
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Bengsch, Bertram; Johnson, Andy L; Kurachi, Makoto et al. (2016) Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity 45:358-73
Sottile, Rosa; Pangigadde, Pradeepa N; Tan, Thomas et al. (2016) HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 46:409-19
Fan, Yiping; Lee, Seungjae; Wu, Gang et al. (2016) Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol 136:339-42
Davar, Diwakar; Kirkwood, John M (2016) Adjuvant Therapy of Melanoma. Cancer Treat Res 167:181-208
Butterfield, Lisa H (2016) Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 65:805-12
Zarour, Hassane M (2016) Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res 22:1856-64
Blackler, Ryan J; Evans, Dylan W; Smith, David F et al. (2016) Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific manner†. Glycobiology 26:181-92

Showing the most recent 10 out of 162 publications